Soluble epoxide hydrolase (sEH) is considered a therapeutic target for multiple cardiovascular diseases including stroke [1] based on the fact that either gene deletion or pharmacological inhibition of sEH have been shown to be neuroprotective after ischemia [2,3]. This evidence concerns the gene EPHX2 and cardiovascular disorder.